PARMEDICS, INC
Temecula, CA · Biotech · Private
Small molecule PAR2 inhibitors for migraine pain treatment
parmedics.com →- Grants
- $3.5M
- 8 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 3
- 0 granted · 3 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20212022202320242025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Development of Small Molecule Antagonists of PAR-2 for treatment of asthma | $283,387 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Development of Small Molecule Antagonists of PAR-2 for treatment of asthma | $283,387 | |
| Federal grant | Department of Health and Human Services · Phase I · Protease-activated-receptor-2 antagonists for treatment of migraine pain | $310,351 | |
| Federal grant | Department of Health and Human Services · Phase I · Protease-activated-receptor-2 antagonists for treatment of migraine pain | $310,351 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of small molecule Protease-activated-receptor-2 antagonists as oral asthma therapeutics | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of small molecule Protease-activated-receptor-2 antagonists as oral asthma therapeutics | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Pharmacokinetic and Efficacy Studies of the Aerosolized PAR2 Antagonist, C781, for the Treatment of Asthma | $878,390 | |
| Federal grant | Department of Health and Human Services · Phase II · Pharmacokinetic and Efficacy Studies of the Aerosolized PAR2 Antagonist, C781, for the Treatment of Asthma | $792,665 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1579 | Vesalius Therapeutics | — | — |
| 1580 | Immunova Therapeutics LLC | — | — |
| 1581 | MIMIVAX VARIA VENTURES LLC | — | $10M |
| 1582 | PARMEDICS, INC | — | — |
| 1583 | Versa Integrated Solutions, Inc. | — | — |
| 1584 | Stem Biotech LLC | — | $100M |
| 1585 | BeneFix, Inc. | — | $8.6M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Small Molecule Modulators Of PAR2 And Uses Thereofapplication
- Small Molecule Modulators Of PAR2 And Uses Thereofapplication
- Small Molecule Modulators Of PAR2 And Uses Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.